Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
|17/05/2018||Notice of General Meeting/Proxy Form||Download|
|15/05/2018||Race appoints Oncologist to head Medical Affairs||Download|
|15/05/2018||Race executes agreement for Bisantrene clinical trial||Download|
|07/05/2018||Interview with Dr John Cullity||Download|
|27/04/2018||Appendix 3Y-Bill Garner||Download|
|20/04/2018||Appendix 4C - quarterly||Download|
|11/04/2018||Race signs global distribution agreement with Durbin PLC||Download|